Mimicking Borderline Resectable Population in Solitary Hepatocellular Carcinoma of BCLC Stage A
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Early recurrence (≤ 6 months) after curative resection of hepatocellular carcinoma (HCC) carries markedly worse prognosis than late recurrence. While borderline resectable (BR1/BR2) HCC is defined anatomically, a biologically high-risk subgroup with BR-like features may exist within resectable (R) disease; we developed and validated a preoperative score to identify such patients within BCLC Stage A primary HCC. Methods We analyzed a single-center discovery cohort of 473 patients with solitary BCLC Stage A primary HCC (2001–2021) and a later validation cohort of 63 patients (2022–2025). An additive 2-factor score (0–2) combined tumor size (≥ 60 mm) and PIVKA-II (≥ 50 mAU/mL); ROC/Youden-index analysis in the same cohort yielded closely similar thresholds. Bootstrap resampling that re-derived cutoffs within each replicate showed a less optimistic, more variable AUC than the fixed-cutoff model. Results Early recurrence occurred in 44/473 (9.3%) discovery patients and carried worse 5-year overall survival than late or no recurrence (38.1% vs. 78.4% vs. 94.6%; p < 0.001). Tumor size ≥ 60 mm (OR 3.94) and PIVKA-II ≥ 50 mAU/mL (OR 2.27) were independent predictors. The score stratified early-recurrence risk in discovery (score 0/1/2: 4.4%/7.7%/27.9%; AUC 0.694, optimism-corrected 0.662–0.692) and validation cohorts (5.6%/12.2%/50.0%; AUC 0.664, 95% CI 0.421–0.870), and was independently associated with distant recurrence after adjustment for early-recurrence status (adjusted OR 3.01 per point, p < 0.001). Conclusions A simple 2-factor score combining tumor size and PIVKA-II identifies, within solitary BCLC Stage A HCC, a high-risk subgroup whose recurrence mimics borderline resectable (BR1) disease. Preoperative (neoadjuvant) systemic therapy in this high-risk group warrants prospective evaluation.
Source: Research Square
Authors: Yoshihiro Sakano, Kunihito Gotoh, Yuki Yokota, Yasunari Fukuda, Hisateru Komatsu, Kaoru Fujikawa, Kei Adachi, Kei Yamamoto, Masatoshi Kitakaze, Yuta Kobayashi, Norihiro Matsuura, Yuki Ushimaru, Kota Momose, Tsuyoshi Hata, Yoshitomo Yanagimoto, Takashi Kanemura, Toshinori Sueda, Yoshinori Kagawa, Kazuyoshi Yamamoto, Hiroshi Miyata, Shogo Kobayashi
Institution: Osaka International Cancer Institute
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hepatocellular carcinoma, BCLC stage A, borderline resectable disease, early recurrence, tumor size, PIVKA-II, preoperative risk score, neoadjuvant systemic therapy, overall survival, distant recurrence, curative resection, prognostic factors, bootstrapping, optimism correction, discovery cohort, prognostic score
Open Access status: green
OpenAlex ID: W7235613219
